Bottom line
PJP vs IYH: the short answer
PJP (Invesco Pharmaceuticals ETF) and IYH (iShares U.S. Healthcare ETF) share a meaningful slice of their top holdings — about 40% by weight.
But IYH is far broader, holding 103 positions to 33 for PJP, so beyond the top names it adds exposure PJP doesn't have.
IYH is cheaper at 0.37% vs 0.58% — a difference of $21 a year per $10,000 invested.
Over five years, PJP returned +9.0% a year vs +7.0% for IYH.
Updated Nov 19, 2026
PJP vs IYH side by side
| PJP | IYH | |
|---|---|---|
| Type | ETF | ETF |
| Fund family | Invesco | iShares |
| Category | Health Care Sector | Health Care Sector |
| Expense ratio | 0.58% | 0.37% |
| Annual cost per $10k | $58 | $37 |
| 10-yr cost on $10k (prospectus) | $726 | $468 |
| Max front load | None | None |
| 12b-1 fee | — | 0% |
| 1-yr return | +27.9% | +13.1% |
| 5-yr return (annualized) | +9.0% | +7.0% |
| 10-yr return (annualized) | +5.1% | +9.4% |
| Best quarter | +18.1% | +15.3% |
| Worst quarter | −14.8% | −12.7% |
| Net assets (fund) | $472.1M | $3.6B |
| Number of holdings | 33 | 103 |
| Portfolio turnover | 36% | 3% |
| Returns as of | Dec 31, 2025 | Dec 31, 2025 |
Source: SEC Form N-PORT and fund prospectuses
Year-by-year returns
| Year | PJP | IYH | Difference |
|---|---|---|---|
| 2025 | +27.9% | +13.1% | +14.8% |
| 2024 | +9.7% | +3.1% | +6.6% |
| 2023 | −2.2% | +2.1% | −4.3% |
| 2022 | −2.0% | −4.4% | +2.4% |
| 2021 | +14.5% | +23.4% | −8.9% |
| 2020 | +11.2% | +15.5% | −4.3% |
| 2019 | +4.7% | +20.8% | −16.1% |
| 2018 | −1.7% | +5.9% | −7.6% |
| 2017 | +15.3% | +22.3% | −7.0% |
| 2016 | −19.3% | −2.8% | −16.4% |
Source: Fund prospectus bar charts
Holdings overlap
10 of PJP's top 25 holdings also appear in IYH's top 25.
| Holding | PJP | IYH |
|---|---|---|
| Abbott Laboratories | 5.67% | 3.02% |
| AbbVie Inc. | 5.48% | 7.32% |
| Amgen Inc. | 5.33% | 3.42% |
| Johnson & Johnson | 5.18% | 10.17% |
| Merck & Co., Inc. | 5.06% | 5.31% |
| Eli Lilly and Co. | 5.02% | 15.11% |
| Gilead Sciences, Inc. | 4.53% | 2.66% |
| Pfizer Inc. | 4.50% | 2.35% |
| Regeneron Pharmaceuticals, Inc. | 3.14% | 1.27% |
| Bristol-Myers Squibb Co. | 2.94% | 2.20% |
Source: SEC Form N-PORT
PJP top 10
- Invesco Private Prime Fund — 7.93%
- Abbott Laboratories — 5.67%
- AbbVie Inc. — 5.48%
- Amgen Inc. — 5.33%
- Johnson & Johnson — 5.18%
- Merck & Co., Inc. — 5.06%
- Eli Lilly and Co. — 5.02%
- Corcept Therapeutics Inc. — 4.96%
- Gilead Sciences, Inc. — 4.53%
- Pfizer Inc. — 4.50%
IYH top 10
- Eli Lilly And Company — 15.11%
- Johnson & Johnson — 10.17%
- Abbvie Inc. — 7.32%
- Unitedhealth Group Incorporated — 6.16%
- Merck & Co., Inc. — 5.31%
- Thermo Fisher Scientific Incorporated — 3.52%
- Amgen Inc. — 3.42%
- Abbott Laboratories — 3.02%
- Gilead Sciences, Inc. — 2.66%
- Pfizer Inc. — 2.35%
FAQ
What is the difference between PJP and IYH?
Which is cheaper, PJP or IYH?
Should I own both PJP and IYH?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.